Skip to content

Clinical study on the treatment of spinal cord injury with injection of mouse nerve growth factor

Clinical study on the treatment of spinal cord injury with injection of mouse nerve growth factor

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500103333
Enrollment
Unknown
Registered
2025-05-28
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal cord injury

Interventions

Test group:Intramuscular injection of mouse nerve growth factor
Control group:None

Sponsors

Xi’an Honghui Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Patients with acute spinal cord injury in the neck, chest, and waist segments, caused by trauma. (2) Age range: 18-70 years old. (3) Good state of consciousness. (4) American Spinal Cord Injury Association (ASIA) injury classification A-C levels; (5) Magnetic resonance imaging examination suggests spinal cord injury; (6) Ensure the completion of the entire research cycle and cooperate in completing rehabilitation training. (7) Voluntarily participate in clinical research, understand and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Primary spinal cord injury combined with severe traumatic brain injury and inability to cooperate with neurological function tests; (2) Patients with unstable vital signs caused by high-level spinal cord injury; (3) Suffering from other systemic diseases and unable to undergo surgical treatment. (4) Suffering from other serious organic diseases or other central nervous system abnormalities that affect symptom analysis, intraoperative observation, or postoperative recovery. (5) Merge with other spinal cord diseases such as spinal deformities, spinal cavities, spinal vascular malformations, ankylosing spondylitis, spinal tumors, etc; (6) Malignant tumor patients; (7) Neurodegenerative disorders: such as dementia, mental disorders, Parkinson's disease, etc; (8) Muscle weakness patients; (9) Analysis of test results for severe impact of central and peripheral nervous system diseases, such as cerebral infarction and ischemic diseases; (10) Patients with peripheral nervous system diseases such as diabetes; (11) Active or aggravating infectious diseases, such as syphilis, AIDS, hepatitis B, etc; (12) Patients who have participated in other clinical trials within the past 6 months

Design outcomes

Primary

MeasureTime frame
ISNCSCI scoring scale;

Secondary

MeasureTime frame
Electromyography;Visual Analogue Scale;

Countries

China

Contacts

Public ContactSiyuan He

Xi’an Honghui Hospital

siyuan_he@whu.edu.cn+86 139 9119 1995

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026